Adenosine Or Derivative Patents (Class 514/46)
-
Patent number: 8906878Abstract: A myocardial imaging method that is accomplished by administering one or more adenosine A2A adenosine receptor agonist to a human undergoing myocardial imaging as well as pharmaceutical compositions comprising at least one A2a receptor agonist, at least one liquid carrier, and at least one co-solvent.Type: GrantFiled: March 21, 2013Date of Patent: December 9, 2014Assignee: Gilead Sciences, Inc.Inventors: Luiz Belardinelli, Mitchell Rosner
-
Publication number: 20140356325Abstract: Compositions and methods relating to 2?-C-methyl nucleoside 5?-monophosphate derivative compounds are provided. In some embodiments, the novel compounds are useful to treat viral infections. In particular, 2?-C-methyl nucleoside 5?-monophosphate derivative compounds, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of viral infection are described.Type: ApplicationFiled: January 8, 2013Publication date: December 4, 2014Applicant: Ligand Pharmaceuticals IncorporatedInventors: Lin Zhi, K. Raja Reddy, Mark David Erion, Scott Hecker
-
Patent number: 8895530Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).Type: GrantFiled: June 4, 2013Date of Patent: November 25, 2014Assignee: Inotek Pharmaceuticals CorporationInventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley, Prakash Jagtap
-
Publication number: 20140336141Abstract: The invention exploits the elucidation of a connection between the S-adenosylmethionine one-carbon cycle and MAO-B levels and describes drug efficacy testing methods and the use of compounds of the S-adenosylmethionine one-carbon cycle as MAO-B inhibitors in disease prevention and treatment.Type: ApplicationFiled: December 21, 2012Publication date: November 13, 2014Inventors: Maria Zellner, Ellen Umlauf
-
Patent number: 8883758Abstract: The invention is directed to 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and pharmaceutical compositions containing them, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds and prodrugs.Type: GrantFiled: May 22, 2013Date of Patent: November 11, 2014Assignee: Anadys Pharmaceuticals, Inc.Inventors: Stephen E. Webber, Gregory J. Haley, Joseph R. Lennox, Alan Xin Xiang, Erik J. Rueden
-
Patent number: 8877732Abstract: The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit.Type: GrantFiled: January 11, 2011Date of Patent: November 4, 2014Assignee: Inotek Pharmaceuticals CorporationInventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley, Rudolf A. Baumgartner
-
Patent number: 8877731Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection.Type: GrantFiled: September 19, 2011Date of Patent: November 4, 2014Assignee: Alios Biopharma, Inc.Inventors: Leonid Beigelman, Jerome Deval, David Bernard Smith, Guangyi Wang, Vivek Kumar Rajwanshi
-
Publication number: 20140323421Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.Type: ApplicationFiled: March 14, 2014Publication date: October 30, 2014Applicant: EPIZYME, INC.Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott R. Daigle, Roy MacFarlane Pollock
-
Publication number: 20140323425Abstract: The present invention describes the use of nucleoside analogues for the treatment of viral infections, in particular of an HIV infection, and also compositions comprising at least one of these analogues, and a method for evaluating the sensitivity to said treatment.Type: ApplicationFiled: October 23, 2012Publication date: October 30, 2014Applicant: Universite Pierre et Marie Curie (Paris 6)Inventors: Vincent Calvez, Anne-Genevieve Marcellin, Cathia Soulie, Melanie Eheve-Quelquejeu, Matthieu Sollogoub
-
Publication number: 20140323424Abstract: Described herein are assays, kits and methods for treating mood disorders by testing for one or more polymorphisms in a specific group of genes and for analyzing the results of polymorphism testing; the genes included may converge in one or more signaling pathways, and may be epigenetic. The genes are included based on the relationships of the proteins encoded by the genes in the context of particular signaling pathways and provide a diagnostically relevant nexus. Also described herein are methods of presenting the data collected by the screen, including methods of delivering interpretive comments and/or treatment guidance based on the results of the genetic screening either individually or based on the genetic composition of particular clusters of genes which may be related to each other. Importantly, drugs which modulate these genetic disturbances are described for targeted therapeutic use based upon companion diagnostic method.Type: ApplicationFiled: July 7, 2014Publication date: October 30, 2014Inventor: Jay L. LOMBARD
-
Patent number: 8871735Abstract: The invention provides a method of reducing infarct size and/or limiting, decreasing and/or inhibiting reperfusion injury and/or ameliorating heart failure in a patient comprising administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to the patient. The compound capable of inhibiting AC5 is particularly effective when administered during or after reperfusion in patients suffering from an ischemic injury.Type: GrantFiled: November 5, 2012Date of Patent: October 28, 2014Assignee: Rutgers, The State University of New JerseyInventors: Stephen F. Vatner, Dorothy E. Vatner
-
Publication number: 20140315849Abstract: The present invention has an object to provide an effective and safe therapeutic agent for inflammatory diseases such as sepsis, hepatitis, and inflammatory bowel disease, and solves the above object by providing a therapeutic agent for inflammatory diseases containing adenosine N1-oxide or a derivative thereof as an effective ingredient.Type: ApplicationFiled: July 3, 2014Publication date: October 23, 2014Inventors: Keizo KOHNO, Emiko OHASHI, Hajime KUSANO, Shigeharu FUKUDA, Tatsuya ISHIHARA
-
Patent number: 8865203Abstract: Compositions and methods to improve the pharmacokinetic profile of S-Adenosylmethionine (SAMe) are provided, as are methods of treating various disorders using SAMe formulations with improved pharmacokinetic profiles. More specifically, the invention is directed to methods of treating a disease or disorder in a subject and/or improving the nutritional status of a subject by administering formulations exhibiting improved pharmacokinetic profiles of exogenous SAMe. The method also includes the step of orally administering compositions of the invention to the subject once per day after overnight fast; that is prior to food intake in the morning.Type: GrantFiled: December 5, 2012Date of Patent: October 21, 2014Assignee: Methylation Sciences International SRLInventors: Nancy Harrison, I. David MacDonald, Aniko Takacs-Cox, Robert Miller
-
Publication number: 20140309188Abstract: A method for treatment of a tumor including administering to a patient in need thereof a pharmaceutical preparation including a combination of a deoxynucleoside and a nucleoside. The deoxynucleoside is selected from deoxyadenosine, deoxyguanosine, deoxycytidine, thymidine, or a mixture thereof. The nucleoside is selected from adenosine, guanosine, cytidine, uridine, deoxyadenosine, deoxyguanosine, deoxycytidine, thymidine, or a mixture thereof.Type: ApplicationFiled: April 17, 2014Publication date: October 16, 2014Inventors: Shizhuang ZHANG, Xin CHENG, Zhiqin GAO, Ming HAN
-
Patent number: 8859522Abstract: This disclosure relates to an improved process for the preparation of regadenoson, pharmaceutically acceptable salts thereof, and hydrates thereof, and for the preparation of intermediates useful in the synthesis of regadenoson. The disclosure also relates to a new crystalline form of regadenoson. Processes for the preparation of the crystalline form, compositions containing the crystalline form, and methods of use thereof are also described.Type: GrantFiled: April 26, 2012Date of Patent: October 14, 2014Assignee: Reliable Biopharmaceutical CorporationInventors: Luzviminda T. Wooldridge, Chun Ma, Sourena Nadji
-
Publication number: 20140303106Abstract: Compounds having methyltransferase inhibitory activity are disclosed. The compounds have the structure and are useful in the treatment of cancer and similar diseases associated with inappropriate methyltransferase activity.Type: ApplicationFiled: October 26, 2012Publication date: October 9, 2014Inventors: Weihong Zheng, Minkui Luo, Glorymar del Valle Ibanzen Sanchez
-
Publication number: 20140301979Abstract: Described herein are 4-methyl-piperazine-1-carbothioic acid amide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by hemorrhagic fever viruses, such as Arenaviruses.Type: ApplicationFiled: June 25, 2014Publication date: October 9, 2014Applicant: SIGA TECHNOLOGIES, INC.,Inventors: Sean M. AMBERG, Dongcheng DAI, Tove C. BOLKEN, Dennis E. HRUBY
-
Patent number: 8846636Abstract: The disclosure provides nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moieties with quaternary centers at the 3? position, the pharmaceutical formulations comprising the analogues, and methods of using the analogues and formulations for treating, preventing, and/or inhibiting diseases or conditions associated with cancers and viruses.Type: GrantFiled: March 18, 2009Date of Patent: September 30, 2014Assignee: LCB Pharma Inc.Inventor: Yvan Guindon
-
Patent number: 8846635Abstract: The present application provides methods and compositions for inducing hepatocyte proliferation and liver regeneration, the latter being mainly dependent on hepatocyte proliferation even if all the other cell types divide to reconstitute the organ specific-lobular-architecture. The methods and compositions provided herein make use of an A3AR agonist. A preferred A3AR agonist disclosed herein is Cl-IB-MECA.Type: GrantFiled: October 22, 2008Date of Patent: September 30, 2014Assignee: Can-Fite Biopharma Ltd.Inventors: Pnina Fishman, Shira Cohen
-
Patent number: 8846118Abstract: The present invention relates to compositions for the protection, treatment and repair of connective tissues in humans and animals comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothionine, one or more avocado/soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.Type: GrantFiled: August 21, 2008Date of Patent: September 30, 2014Assignee: Nutramax Laboratories, Inc.Inventors: Todd R. Henderson, Tarek Hammad, Medhat Soliman, Barbara E. Corson, Louis Lippiello, Robert W. Henderson
-
Patent number: 8841275Abstract: Disclosed herein are 2?-spiro-nucleosides and derivatives thereof useful for treating a subject infected by hepatitis C virus or dengue virus.Type: GrantFiled: November 30, 2011Date of Patent: September 23, 2014Assignee: Gilead Pharmasset LLCInventors: Jinfa Du, Michael Joseph Sofia
-
Patent number: 8841276Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are fulvene and/or fulvalene analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, as well as numerous inflammatory, degenerative and vascular diseases, including various ocular diseases. Representative fulvene and/or fulvalene analogs include fulvene and fulvalene analogs of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function, at least, by inhibiting Nox or ROS. In some embodiments, the Nox is one that is selectively expressed in cancer cells over normal cells, or one that is expressed in higher amounts in cancer cells over normal cells. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.Type: GrantFiled: August 20, 2013Date of Patent: September 23, 2014Assignees: Emory University, The United States of America as represented by the Department of Veterans AffairsInventor: Jack L. Arbiser
-
Publication number: 20140271945Abstract: A method of detecting the presence or absence of a disease in a patient wherein said disease is accompanied by deficient levels of S-adenosylmethionine comprising: identifying a patient that is suspected of having said disease or is at risk of having said disease; obtaining a biological sample from said patient; determining the level of S-adenosylmethionine in said biological sample using an antibody derived from a hapten analog of S-adenosylmethionine; and correlating the level of S-adenosylmethionine in said biological sample with the presence or absence of said disease. The invention also provides methods for measuring SAH which is used to determine the methylation index (ratio of SAM/SAH) in biological fluids which is indicative of the health status of an individual.Type: ApplicationFiled: March 18, 2014Publication date: September 18, 2014Inventors: Xiujuan Hao, Isaac A. Angres
-
Publication number: 20140256668Abstract: The present disclosure relates to compounds of formula (I-A) using the compounds wherein Ring A and the variables X, Y, R3a, R3b, R3c, R3d, R4, R5, R5?, and m are defined herein, to pharmaceutical compositions comprising the compounds, and methods of using the compounds.Type: ApplicationFiled: May 23, 2013Publication date: September 11, 2014Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Stephen CRITCHLEY, Thomas G. Gant, Steven P. Langston, Edward J. Olhava, Stephane Peluso
-
Publication number: 20140255492Abstract: Fine dry particulate adenosine compositions suitable for use in topical formulations, as well as methods of making the same, are provided. In the dry particulate adenosine composition, the adenosine active agent is associated with the particles, e.g., via entrapment in the pores of the particles and/or ionic binding and/or non-covalent binding to the surface of the particles and/or loosely associated with the particles. Also provided are topical formulations which include the dry particulate adenosine compositions of the invention, and methods of using the same.Type: ApplicationFiled: August 16, 2012Publication date: September 11, 2014Applicant: LABORATORY SKIN CARE, INC.Inventor: Zahra Mansouri
-
Publication number: 20140256669Abstract: A method for controlling a pest on a crop includes applying a pesticide that comprises N6-(2-hydroxyethyl)-adenosine as an active ingredient for controlling the pest. The pesticide may include 20 wt % N6-(2-hydroxyethyl)-adenosine, 1-3 wt % dispersing agent, and 66.5% wt % water. The pesticide may further include a dispersion agent, a thickening agent, or an antifreeze agent as an auxiliary agent. The dispersing agent may be one or more selected from sodium lignin sulfonate, NNO, Agricultural Emulsifier 500#, Agricultural Emulsifier 700#, Agricultural Emulsifier 600#, Agricultural Emulsifier 1602#, methylene bis-methylnaphthalene sodium sulfonate, sodium salt of alkyl naphthalene sulfonate condensate, or polyoxyethylene castor oil. The thickening agent may be one or more selected from carboxymethyl cellulose, urea, poly vinyl alcohol, aluminum magnesium silicate, or xanthan gum.Type: ApplicationFiled: March 6, 2014Publication date: September 11, 2014Applicant: ZHEJIANG SUBTROPICAL CROPS RESEARCH INSTITUTEInventors: Yiqiu Chai, Guanju Chen, Yiwei Jin, Yougao Liu, Xiaola Li, Xiangli Dang
-
Publication number: 20140248270Abstract: A method of treating a tar-responsive dermatological disorder includes topically applying an anhydrous tar composition to skin of a mammal, preferably a human, that is involved with the disorder, the composition including a wax and a therapeutically effective amount of tar for topical treatment of the tar-responsive dermatological disorder, the composition being in liquid form when at a temperature selected from room temperature and a temperature of skin of a mammal upon application of the composition to the skin of the mammal.Type: ApplicationFiled: May 13, 2014Publication date: September 4, 2014Inventors: Ruey J. YU, Eugene J. VAN SCOTT
-
Publication number: 20140248241Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3?-deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base1 and Base2 are as provided herein.Type: ApplicationFiled: March 3, 2014Publication date: September 4, 2014Inventors: Alistair James STEWART, Adel M. MOUSSA, Benjamin Alexander MAYES, Francois-Rene ALEXANDRE, Dominique SURLERAUX, Christophe Claude PARSY, Claire PIERRA, David DUKHAN, Gilles GOSSELIN
-
Publication number: 20140241990Abstract: Disclosed herein are methods for treating depression and depressive-like symptoms by administering a therapeutically effective amount of an adenosine 1 receptor agonist. Also disclosed herein are methods for identifying adenosine receptor agonists and the use of identified adenosine receptor agonists for treating diseases, disorders or conditions characterized by pathological sleep perturbations.Type: ApplicationFiled: September 28, 2012Publication date: August 28, 2014Applicant: TUFTS UNIVERSITYInventors: Philip G. Haydon, Dustin J. Hines, L. Ian Schmitt
-
Publication number: 20140235563Abstract: Embodiments of the invention are to compounds, methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention are 2?,4?-substituted nucleoside compounds useful for the treatment of viral infections, such as HIV, HCV, and HBV infections.Type: ApplicationFiled: April 30, 2014Publication date: August 21, 2014Applicants: Gilead Sciences, Inc., Gilead Pharmasset LLCInventors: Michael Joseph Sofia, Jinfa Du
-
Publication number: 20140235562Abstract: A method of treating an ocular disorder in a subject includes administering to the subject a therapeutically effective amount of an agent that modulates at least one target in a signaling cascade associated with light induced retinal degeneration, aberrant all-trans-retinal accumulation, and/or generation of reactive oxygen species (ROS).Type: ApplicationFiled: April 25, 2014Publication date: August 21, 2014Inventors: Krzysztof Palczewski, Yu Chen
-
Patent number: 8809298Abstract: Methods are presented that comprise the administration of a pharmaceutical composition comprising adenosine and dipyridamole, as well methods comprising the combined administration of dipyridamole administered as a bolus with adenosine given as an infusion, both at dosages below their respective single agent dosages, for detecting the presence and/or assessing the severity of myocardial ischemia during pharmacologic stress tests. The methods are useful for exploiting the vasodilating abilities of adenosine at doses at which side effects related to adenosine are substantially reduced while optimal coronary artery perfusion is achieved. Also presented are compositions, unit dosage forms, and kits that are useful in performing the methods.Type: GrantFiled: August 20, 2010Date of Patent: August 19, 2014Assignee: Adenobio N.V.Inventor: Philippe Gorny
-
Patent number: 8809299Abstract: Described are methods and compositions for treating cancer that include a dopamine receptor (DR) antagonist such as thioridazine and a chemotherapeutic agent. Optionally, the chemotherapeutic agent is a DNA synthesis inhibitor such as cytarabine or a microtubule inhibitor such as paclitaxel or docetaxel. The methods and compositions are useful for the treatment of cancers such as acute myeloid leukemia.Type: GrantFiled: March 15, 2013Date of Patent: August 19, 2014Assignee: McMaster UniversityInventors: Mickie Bhatia, Eleftherios Sachlos
-
Publication number: 20140227260Abstract: The present invention relates to new aminopyrimidine inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: April 21, 2014Publication date: August 14, 2014Applicant: Auspex Pharmaceuticals, Inc.Inventor: Chengzhi Zhang
-
Publication number: 20140227239Abstract: It is an object of the present invention to provide a growth hormone secretagogue that is excellent in effect of promoting secretion of a growth hormone and is orally available. The growth hormone secretagogue of the present invention contains one or more selected from the group consisting of S-adenosylmethionine and/or a salt thereof, a Siberian larch extract, an olive extract, and a stilbene-based compound as an active ingredient. S-adenosylmethionine and/or the salt thereof may be a form itself of chemically synthesized S-adenosylmethionine and/or the salt thereof, or may be a microbial cell or a culture containing S-adenosylmethionine and/or the salt thereof. The stilbene-based compound may be an extract extracted from a Vitaceae plant or a Gnetaceae plant. The olive extract may be an extract separated from a fruit of olive.Type: ApplicationFiled: March 2, 2012Publication date: August 14, 2014Applicant: LION CORPORATIONInventors: Toshio Gokita, Ikuko Kamada, Kiwamu Suzuki, Hiroaki Kambayashi
-
Publication number: 20140220129Abstract: Provided herein are compositions and formulations comprising S-adenosyl-L-methionine (“SAM-e” or “SAMe”) and one or more gallic acid esters. Also provided herein are methods for improving the delivery of SAMe. Compositions and formulations provided herein increase SAMe plasma concentrations and area under the curve (AUC) values. Also provided herein are methods of treating a disease or disorder in a subject by administering compositions or formulations comprising exogenous SAMe and one or more gallic acid esters.Type: ApplicationFiled: April 7, 2014Publication date: August 7, 2014Applicant: Methylation Sciences International SRLInventors: Dechi GUAN, I. David MACDONALD
-
Publication number: 20140219957Abstract: The invention features methods of treating an immune disorder characterized by elevated Pin1 marker levels in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating immune disorders (e.g., immune disorders characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination with an anti-inflammatory, anti-viral, or anti-microbial compound.Type: ApplicationFiled: May 29, 2012Publication date: August 7, 2014Applicant: Beth Israel Deaconess Medical Center, Inc.Inventors: Kun Ping Lu, Adrian Tun-Kyi, Greg Finn
-
Patent number: 8796241Abstract: Methods for treating diseases in humans and vertebrate animals are provided using competitive antagonists of cellular metabolites combined with a protective agent for protecting host cells from toxic effects of the drugs. Also provided are kits comprising competitive antagonists and suitable protective agents. In addition, screening methods for identifying competitive antagonists, protective agents and potentiating agents, for use according to the methods of the invention, are provided.Type: GrantFiled: August 15, 2008Date of Patent: August 5, 2014Inventors: Adam Lubin, Martin Lubin
-
Publication number: 20140213542Abstract: The present invention relates to a composition including S-adenosyl-L-methionine; and at least one kind of additive selected from carboxymethylcellulose, hydroxypropylcellulose, soybean polysaccharide, casein sodium, and zein, in which S-adenosyl-L-methionine is extracted from S-adenosyl-L-methionine-containing cells obtained by culturing a microorganism having an ability to produce SAMe, and the content of the additive in the composition falls within the range of 0.05 to 15 times by mass of S-adenosyl-L-methionine in the composition. The present invention provides a composition containing a high concentration of S-adenosyl-L-methionine, which is useful as a water-soluble physiologically active substance, and being excellent in storage stability and bioabsorbability. The present invention also relates to a molded article formed by using the composition and a method of producing the composition.Type: ApplicationFiled: July 20, 2012Publication date: July 31, 2014Applicant: MITSUBISHI GAS CHEMICAL COMPANY, INC.Inventors: Kentaro Takano, Shinyo Gayama
-
Publication number: 20140213541Abstract: The present invention relates to a method for treating recurrent tumor metastases following liver resection that includes administration of an effective amount of an agonist of A2A adenosine receptors (ARs).Type: ApplicationFiled: October 7, 2013Publication date: July 31, 2014Applicant: ADENOSINE THERAPEUTICS, LLCInventors: Onno Kranenburg, Jamila van der Bilt, Inne Borel Rinkes, Jayson M Rieger
-
Publication number: 20140213540Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.Type: ApplicationFiled: March 20, 2014Publication date: July 31, 2014Applicants: IDENIX PHARMACEUTICALS, INC., L'UNIVERSITE MONTPELLIER II, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITA DEGLI STUDI DI CAGLIARIInventors: Richard STORER, Gilles GOSSELIN, Jean-Pierre SOMMADOSSI, Paolo LACOLLA
-
Publication number: 20140205680Abstract: Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.Type: ApplicationFiled: October 17, 2013Publication date: July 24, 2014Applicant: SUNESIS PHARMACEUTICALS, INC.Inventors: Daniel C. Adelman, Jeffrey A. Silverman, Michelle Arkin, Jennifer Hyde, Duncan Walker, Jasmin Wright
-
Publication number: 20140206639Abstract: The present invention provides pharmaceutical compositions comprising a dihydro base described herein (e.g., compound DHdC). The dihydro base may show multiple tautomerism and may increase mutation of an RNA and/or DNA of a virus or cancer cell. The dihydro base may be used to reduce DNA methylation (e.g., in a cancer cell). The present invention also provides kits including the inventive pharmaceutical compositions and methods of treating a viral infection (e.g., influenza, HIV infection, or hepatitis C) or cancer using the pharmaceutical compositions or kits.Type: ApplicationFiled: January 22, 2014Publication date: July 24, 2014Applicant: Massachusetts Institute of TechnologyInventors: John M. Essigmann, Deyu Li, Katherine J. Silvestre
-
Patent number: 8785415Abstract: Provided are compositions of cladribine and cyclodextrin which are especially suited for the oral administration of cladribine.Type: GrantFiled: January 7, 2011Date of Patent: July 22, 2014Assignee: Ares Trading S.A.Inventors: Nicholas S. Bodor, Yogesh Dandiker
-
Publication number: 20140187509Abstract: The present invention provides a method of preventing or treating cardiovascular dysfunction by administering a therapeutically effective amount of (a) one or more of (i) S-adenosylmethionine or a derivative or pharmaceutically acceptable salt thereof and (ii) N-acetylcysteine or a derivative or pharmaceutically acceptable salt thereof; (b) vitamin E or a derivative or pharmaceutically acceptable salt thereof; and (c) vitamin C or a derivative or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 13, 2012Publication date: July 3, 2014Applicant: SCIMAR LTD.Inventors: Wilfred Wayne Lautt, Zhi Ming
-
Publication number: 20140186468Abstract: The present invention provides a unique combination of biomarkers that identify triple-negative breast cancer (TNBC) patient subpopulations. Such subpopulations will have differential responses to therapies, and thus treatments can be tailored to particular patients.Type: ApplicationFiled: December 6, 2013Publication date: July 3, 2014Inventors: Susana GONZALO, Adriana DUSSO, Xavier MATIAS-GUIU, Anna Novell ALVAREZ, Ignacio GONZALEZ-SUAREZ, David GROTSKY
-
Patent number: 8765710Abstract: Embodiments of the invention are to compounds, methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention are 2?,4?-substituted nucleoside compounds useful for the treatment of viral infections, such as HIV, HCV, and HBV infections.Type: GrantFiled: December 13, 2011Date of Patent: July 1, 2014Assignee: Gilead Pharmasset LLCInventors: Michael Joseph Sofia, Jinfa Du
-
Patent number: 8765935Abstract: The invention provides a compound of formula (I), wherein R1-R6 and X have any of the values described, as well as pharmaceutical compositions comprising such compounds and therapeutic methods comprising the administration of such compounds.Type: GrantFiled: January 29, 2013Date of Patent: July 1, 2014Assignee: Regents of the University of MinnesotaInventor: Carston R. Wagner
-
Publication number: 20140178372Abstract: The present application relates to treatment of hematologic cancers, which treatments can include, e.g., administration of a purine nucleoside phosphorylase (PNP) inhibitor, an alkylating agent and/or an anti-CD20 agent, and related compositions and kits.Type: ApplicationFiled: February 26, 2014Publication date: June 26, 2014Applicant: BIOCRYST PHARMACEUTICALS, INC.Inventors: Shanta BANTIA, Philip BREITFELD, Yarlagadda S. BABU
-
Publication number: 20140178354Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.Type: ApplicationFiled: December 23, 2013Publication date: June 26, 2014Applicant: The Regents of the University of CaliforniaInventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H.R. Feling